Participated · Series A · Mar 2026

Scala Biodesign builds ScalaOS, a production-grade protein design platform that integrates physics-based modeling, evolutionary data, and LLM-based AI models to optimize protein performance. The platform targets applications across antibodies, enzymes, vaccines, diagnostics, and industrial biotechnology, and aims to reduce experimental iterations by producing higher-performing designs often in a single design cycle. Over the past eight months ScalaOS has onboarded nine of the world’s top 20 pharmaceutical companies and engaged leading chemical corporations. A highlighted collaboration with Boehringer Ingelheim reportedly stabilized multiple challenging drug targets, improving expression and activity to advance discovery programs. Scala was founded in 2022 by Dr. Ravit Netzer and Dr. Adi Goldenzweig, with Chief Scientist Prof. Sarel Fleishman, and is based in Tel Aviv, Israel. The company has translated more than a decade of validated protein design research and 150+ publications into an enterprise-ready software platform for industry R&D.

Led · Series B · Jul 2024

Addionics produces textured, three-dimensional copper and aluminum foil current collectors for lithium-ion batteries, using electro-deposition for copper and electroetching for aluminum. Its foils feature tiny holes and undulating peaks and valleys that increase contact between the foil and active material. The company says the design improves battery performance and efficiency and can potentially double battery lifespan, and that the collectors can work with a wide range of chemistries. Addionics plans to tailor collectors to different chemistries in the future to extract additional performance. The Israel- and U.K.-based startup recently raised a $39 million Series B to accelerate delivery of its current collectors and to explore new markets and geographies. Earlier this year it announced plans to build a $400 million factory in the U.S. and said it has letters of intent from U.S. automakers. Addionics develops patented Smart 3D Electrode architecture and a scalable electrode fabrication process that replaces traditional 2D layered electrodes, aiming to increase energy density, power, safety and lifetime without raising cost. Its drop-in solution is compatible with existing battery manufacturing lines and is paired with a proprietary AI algorithm to accelerate and optimize electrode design for varied applications. The company targets electric vehicles initially and is collaborating with automotive OEMs and suppliers in the U.S. and Europe to integrate with NMC, LFP, silicon, lithium polymer and solid-state chemistries. Addionics plans to commercialize by 2024 and will use funding to advance product development, expand the team, and increase activity in the U.S. and Germany. The company also highlights applications beyond EVs, including consumer electronics, stationary storage, aviation, defense and medical devices. Addionics has developed a scalable, patent‑protected “smart 3D structure” that redesigns battery architecture via 3D metal fabrication to reduce internal resistance and improve mechanical longevity and thermal stability. The company’s approach is chemistry‑agnostic, designed to enhance existing and future battery chemistries rather than replace them. Addionics says its technology can increase EV mileage, improve safety, and reduce cost and charging time, and could be applied to consumer electronics, medical devices, grid storage, drones, and more. Commercial traction is early: the company is working with an unnamed tier‑1 American automotive company on a proof‑of‑concept and testing Addionics cells in vehicles. Management aims to secure 3–4 major collaborations with world‑leading OEMs over the next year. Financially, the company has raised $6M in funding, which includes a $2.5M grant awarded through the European Union’s Horizon2020 program.

Participated · Series A · Jun 2024

Exsilio Therapeutics develops genomic medicines designed to permanently insert therapeutic genes via RNA intermediate templates and deliver them in lipid nanoparticles. Its technology is based on naturally occurring genetic elements engineered through predictive in silico modeling and wet lab experimentation for precise insertion into safe-harbor sites of disease-relevant cells. The company aims to treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions, by encoding genes that integrate permanently rather than producing transient effects. Exsilio plans to use its platform to insert whole genes with a repeatable and titratable approach, potentially addressing patients irrespective of individual mutations. Led by CEO Tal Zaks, the company intends to advance lead candidates toward development and expand operations using the new financing. The article does not disclose revenue or user metrics.

Led · Equity · Apr 2024

Greeneye Technologies, founded in 2017 and led by CEO Nadav Bocher, develops AI-enabled precision spraying technology to offer sustainable alternatives to conventional crop protection. The company harnesses AI and deep machine learning to make intelligent, real-time decisions in the field that are proven to cut chemical use and improve weed-control efficacy versus standard broadcast spraying. Greeneye aims to increase productivity and profitability for farmers while addressing environmental challenges and global food production demand. The firm plans to use the new funding to scale its U.S. operations, advance the technology's analytical capabilities, and extend usage to new inputs and crops. Financially, the company announced a $20M funding raise led by Deep Insight. Greeneye Technology makes an AI-based precision spraying system that retrofits existing machines with cameras and sensors so the system recognizes weeds in real time and sprays only targeted areas. In on-farm field trials the system reduced non-residual herbicide use by an average of 86% while achieving the same weed control and yield as traditional broadcast spraying; a University of Nebraska–Lincoln ARD trial showed an 87% reduction in post-emergence use and a 94% reduction in burndown applications. Greeneye reported trial cost savings of $24.70/acre for pre-emergence and $40.50/acre for post-emergence applications. The company launched the technology in early 2022, said demand exhausted available units for 2023, and treated “tens of thousands of acres” last year. Greeneye plans to scale commercial deployments via partnerships and is targeting a U.S. launch with FBN members for the 2024 growing season, with expansion to Canada and possibly South America under consideration. The product is positioned to lower input costs, improve efficacy, and enable new crop-protection programs by making precise spraying more affordable. Greeneye develops proprietary AI-enabled precision spraying technology that uses deep machine learning to enable intelligent, real-time decisions for precise application of herbicides and other chemicals. The company announced the commercial launch of its technology in October 2021. Greeneye completed a $22M funding round to support commercialization and growth. Proceeds will fund a U.S. commercial launch in 2022 and expansion across North America in 2023, and will be used to advance analytical capabilities and extend use to new inputs and crops. Ahead of these milestones Greeneye will double its R&D team in Israel and its sales and operations team in the U.S. The company was founded in 2017 in Tel Aviv by CEO Nadav Bocher. Greeneye Technology, founded in 2017 and based in Tel Aviv, develops an artificial intelligence platform to detect and spray weeds in real time. Its selective spraying (SSP) system can integrate into any agricultural sprayer by retrofitting existing sprayers or via collaboration with sprayer manufacturers to deliver plant-level variable-rate spraying. The platform maps entire fields with cameras at plant-level resolution and enables targeted, selective applications. The company intends to use the funds to advance product research and development and to expand strategic partnerships with sprayer manufacturers and other stakeholders. Greeneye has attracted participation from both venture and industry investors. Following the round, JVP Partner Michal Drayman and Syngenta Ventures' Managing Director Shubhang Shankar joined Greeneye's board.

Participated · Series B · Apr 2024

Magnus Metal has developed a "digital casting" process that slices designs into layers and creates ceramic forms 4–20 mm thick into which molten metal is dripped and built up layer by layer. Each new layer melts the previous one to bond material and allow impurities to float out, yielding parts the company says have fewer defects and are 10%–20% stronger than traditionally cast parts. The system is positioned as faster than 3D printing, able to use customer-specified materials, and its ceramic bases can be reused for a finite number of parts. Magnus says the approach removes the need for expensive tooling used in sand casting, making lower-volume, complex parts more cost-effective while acknowledging simple parts will still favor sand casting. The company plans to sell both machines and proprietary ceramic feedstock, targeting $500,000 to $1 million of recurring revenue per machine. Magnus Metal has raised a $74 million Series B to support industrialization this year and to begin beta testing at the start of next year.